1416820-84-2

Upstream product

• 482656-47-3 ethyl (2R)-3-[4-(benzyloxy)phenyl]-2-hydroxypropanoate 
• 1416820-83-1 ethyl (2R)-2-ethoxy-3-{4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl}propanoate 
• 847268-21-7 ethyl (2R)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoate 
• 373368-68-4 (R)-3-[4-(benzyloxy)phenyl]-2-hydroxypropanoic acid 
• 222555-05-7 ethyl (2R)-2-ethoxy-3-(4-hydroxyphenyl)propanoate 

Relevant academic research and scientific papers

PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES

The present invention relates to hydroxamate compounds and pharmaceutical compositions that are useful for treating and/or preventing metabolic inflammation mediated diseases such as diabetes, obesity, hypertension, dyslipidemia, a neurodegenerative disorder (e.g., Alzheimer's disease, Parkinson's disease, or Huntington's disease), or any combination thereof. Moreover, the present invention also provides methods of treatment for these diseases or disorders.

PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

The present invention relates to PPARy- sparing compounds and pharmaceutical compositions formulated with such compounds that are useful for treating, delaying the onset of, or reducing the symptoms of a neurodegenerative disorder including Huntington's disease, epilepsy, AMS, and MS.

PPAR-SPARING COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND OTHER METABOLIC DISEASES

The present invention relates to compounds and pharmaceutical compositions that are useful for treating and/or preventing diabetes or other metabolic diseases, optionally in combination with a second therapy such an active pharmaceutical agent or diet restriction or an increase in duration or exertion in physical activity.